[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastritis-associated-with-helicobacter-pylori\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastritis-associated-with-helicobacter-pylori":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100611785","phase-2-premedication-with-n-acetylcysteine-and-simethicone-to-improve-mucosal-visualization-in-elective-upper-endoscopy-100611785",false,"NCT07245095","Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy","Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score","NACSIMET","Inclusion Criteria:\n\n* Men and women aged 18 to 70 years old.\n* Patients who agree to participate in the clinical trial.\n* Patients without active gastrointestinal bleeding.\n* Signing of informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to N-acetylcysteine\n* Patients with a history of hypersensitivity to simethicone\n* Patients with a previous endoscopic diagnosis\n* Patients with a history of gastric or bariatric surgery\n* Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis)\n* Patients taking medications that delay gastric emptying (GLP-1 analogues)\n* Pregnant or breastfeeding patients\n* Patients who do not agree to participate in the clinical trial",true,"ALL","18 Years","99 Years",{"count":22,"type":23},132,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.\n\nThe main questions this study aims to answer are:\n\nDoes pre-endoscopy administration of N-acetylcysteine\u002Fsimethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?\n\nIs this combination safe and well tolerated in this patient population?\n\nResearchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.\n\nParticipants will:\n\nReceive a single oral dose of either N-acetylcysteine\u002Fsimethicone or placebo prior to endoscopy\n\nUndergo a routine upper GI endoscopy\n\nHave mucosal cleanliness evaluated using the TUGS scoring system\n\nBe monitored for any adverse events or intolerance",[29,30,31,32,33,34,35,36,37,38],"Esophagogastroduodenoscopy","Simethicone","N-Acetylcysteine","Premedication","Visualization","Esophagogastroduodensocopy (EGD) Procedure","Placebo - Control","Gastritis Associated With Helicobacter Pylori","Tumor Gastric","Lesions in the Esophagus, Stomach, Duodenum or Rectum",[29,40,32,30,41,42],"Mucous Membrane","Acetylcysteine","Gastrointestinal Tract","RECRUITING","2025-11-20",{"date":46,"type":47},"2025-11-24","ACTUAL",{"date":49,"type":47},"2025-09-12",{"date":51,"type":23},"2026-12-31",{"name":53,"class":54},"Hospital General de Mexicali","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":5},"100606721","phase-2-efficacy-of-carminal-in-helicobacter-pylori-gastritis-100606721","NCT07179237","Efficacy of Carminal in Helicobacter Pylori Gastritis","Evaluation of the Efficacy of Carminal on the Gastric Mucosa in Patients With Helicobacter Pylori Positive Gastritis","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients with clinical symptoms of dyspepsia\n* Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology\n* Patients who give written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with peptic ulcer disease\n* Patients with previous gastric surgery\n* Patients with current malignancy or the history of any previous malignancies\n* Patients taking another investigational product, or have taken any investigational product in the last year\n* Patients with known hypersensitivity to any ingredients found in the investigational product.\n* Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver disease, and psychiatric illnesses that may limit adherence to the requirements of the clinical trial, or any other special condition that, according to the physician's judgement, jeopardises the patient's health or life during participation in the trial.\n* Planned pregnancy for the duration of trial, pregnancy, breast feeding, or postpartum period.\n* Patients with human immunodeficiency virus (HIV).",{"count":63,"type":23},80,[26],"Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa. Treatment with Carminal will be continued after successful HP eradication during 12 weeks. The final evaluation will take place 12 weeks after the last Carminal intake, when control endoscopy with histology will be performed. The study will last approximately 24 weeks.",[67,68,69,36,70],"H Pylori Gastritis","H Pylori Infection","H Pylori Eradication","Gastric Mucosal Lesion",[72,73,74,75,76,77],"Antioxidant","Aloe vera","Food Supplement","Helicobacter Pylori","Gastritis","Gastric mucosa","2025-09-16",{"date":80,"type":47},"2025-09-17",{"date":82,"type":47},"2025-08-04",{"date":84,"type":23},"2026-10-05",{"name":86,"class":87},"Catalysis SL","INDUSTRY"]